bitopertin

Phase 3Small molecule

Roche

bitopertin is one of 128 small molecule programs targeting Diamond-Blackfan anemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

127

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diamond-Blackfan AnemiaActive, not recruiting

Erythropoietic ProtoporphyriaActive, not recruiting

Beta-ThalassemiaActive, not recruiting

SchizophreniaActive, not recruiting

Obsessive-Compulsive DisorderActive, not recruiting

Diamond-Blackfan AnemiaPhase 1/Phase 2

Active, not recruiting

Erythropoietic ProtoporphyriaPhase 1

Active, not recruiting

Beta-ThalassemiaPhase 2

Active, not recruiting

SchizophreniaPhase 3

Active, not recruiting

Obsessive-Compulsive DisorderPhase 2

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

bitopertin

Roche

Phase 3

5 2

Celexa

AbbVie

Preclinical

4 3

Ozempic

Novo Nordisk

Preclinical

1 4

Resotran

Takeda

Preclinical

1 5

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 6

Zocor

OOrganon and Co

Preclinical

6 7

Depakote

Ibrance

Lunesta

3 10

Comtan

Orion Corporation, Orion Pharma

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schizophrenia5 trials

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)

Completed· Roche logo

Roche·Phase 3·NCT01235559·604 enrolled

A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

Completed· Roche logo

Roche·Phase 3·NCT01192906·624 enrolled

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)

Completed· Roche logo

Roche·Phase 3·NCT01235585·597 enrolled

Show 2 more trials

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

Completed· Roche logo

Roche·Phase 2·NCT01234779·301 enrolled

A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia

Completed· Roche logo

Roche·Phase 3·NCT01192880·625 enrolled

Single Dose1 trial

A Study Exmining the Effect of Multiple Doses of Bitopertin on the Single Dose Pharmacokinetics of Midazolam in Healthy Volunteers.

Withdrawn· Roche logo

Roche·Phase 1·NCT02019290

Obsessive-Compulsive Disorder1 trial

A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)

Completed· Roche logo

Roche·Phase 2·NCT01674361·99 enrolled

Erythropoietic Protoporphyria1 trial

Effect of Bitopertin on the Liver and on Levels of Protoporphyrin IX in Bile, Blood, Liver, and Stool in Patients With Erythropoietic Protoporphyria/X-linked Protoporphyria and Increased Liver Stiffness and/or Liver Enzymes at Baseline

Withdrawn·WWake Forest University Health Sciences·Phase 1·NCT07123363

Beta-Thalassemia1 trial

A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia

Completed· Roche logo

Roche·Phase 2·NCT03271541·12 enrolled

2 more indications

Diamond-Blackfan anemia1 trial

A Phase I/II, Intra-Patient Dose-Escalation Study of the Selective GlyT1 Inhibitor, Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia.

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Preclinical·NCT05828108·15 enrolled

Unspecified1 trial

A Study of Bitopertin (RO4917838) in Healthy Male Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01636492·71 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for bitopertin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — bitopertin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for bitopertin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

bitopertin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Schizophrenia5 trials

Single Dose1 trial

Obsessive-Compulsive Disorder1 trial

Erythropoietic Protoporphyria1 trial

Beta-Thalassemia1 trial

Diamond-Blackfan anemia1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News